How should dabigatran (Pradaxa) be managed in a patient scheduled for fracture repair?

Management of Dabigatran (Pradaxa) for Fracture Repair Surgery

Stop dabigatran 3 days before fracture repair surgery (skip 4 doses) if the patient has normal or mildly impaired renal function (CrCl ≥50 mL/min), or 4-5 days before surgery (skip 6-8 doses) if moderate renal impairment exists (CrCl 30-50 mL/min). 1

Preoperative Management Algorithm

Step 1: Assess Renal Function

Calculate creatinine clearance (CrCl) using the Cockcroft-Gault formula immediately, as dabigatran elimination is heavily dependent on kidney function 1.

Step 2: Determine Bleeding Risk of Fracture Repair

Fracture repair surgery (particularly hip fractures requiring open reduction or arthroplasty) is classified as high bleeding risk surgery because:

• Surgical hemostasis must be optimal
• Significant blood loss is expected
• Neuraxial anesthesia may be required

Step 3: Time the Last Dabigatran Dose

For patients with CrCl ≥50 mL/min:

• Give last dose 3 days before surgery (skip 4 doses)
• This allows 4-5 half-lives (48-60 hours) to elapse
• Results in minimal residual anticoagulant effect at surgery 1

For patients with CrCl 30-50 mL/min:

• Give last dose 4-5 days before surgery (skip 6-8 doses)
• Dabigatran half-life extends to 16-18 hours with moderate renal impairment
• Requires 64-90 hours for adequate clearance 1

For patients with CrCl <30 mL/min:

• The FDA label provides no specific recommendations 2
• Consider even longer interruption periods (5+ days)
• Strongly consider measuring dabigatran levels if available

Step 4: Consider Laboratory Monitoring (If Available)

While not routinely necessary when following recommended interruption periods 3, laboratory monitoring can be valuable in specific situations:

• Target dabigatran level: <50 ng/mL for high bleeding risk surgery 4, 5
• Use ecarin chromogenic assay (ECA) if available for quantitative measurement
• Alternative: aPTT, thrombin time (TT), or diluted thrombin time (Hemoclot®) 6
• Critical caveat: Standard coagulation tests (PT/INR) are unreliable for dabigatran monitoring 2

Step 5: Do NOT Use Bridging Anticoagulation

No preoperative heparin bridging (LMWH or UFH) is needed when following the recommended interruption periods 3. Bridging is only considered for extremely high thrombotic risk patients, which is rare in the fracture repair setting.

Postoperative Resumption

Timing Based on Bleeding Risk

For high bleeding risk surgery (fracture repair):

• Resume dabigatran 2-3 days after surgery (48-72 hours postoperative) 1
• Start with reduced dose: 150 mg once daily for first 2 days 1
• Then advance to full dose: 150 mg twice daily 1

Alternative for very high thrombotic risk patients:

• Consider 110-150 mg once daily on evening after surgery 1
• This mirrors the dosing used in orthopedic thromboprophylaxis studies

Ensure Adequate Hemostasis

• Confirm surgical hemostasis is adequate before resuming
• Wait at least 24 hours minimum, even for lower-risk procedures
• The rapid onset of action (peak levels in 1-3 hours) means full anticoagulation occurs quickly 1

Critical Pitfalls to Avoid

1. Don't rely on INR: Dabigatran increases INR but this does not reflect warfarin effect or bleeding risk 2

2. Don't underestimate renal impairment: Elderly fracture patients often have declining renal function. A "normal" creatinine may mask significant impairment due to low muscle mass. Always calculate CrCl 1

3. Don't rush resumption: The 48-72 hour delay for high bleeding risk surgery is evidence-based. Early resumption risks surgical site bleeding 1

4. Don't open or crush capsules: Dabigatran must be swallowed whole; breaking capsules increases exposure and bleeding risk 2

5. Don't assume 24 hours is enough: While some patients in RE-LY had surgery after 24 hours, the standardized protocol used 3+ days for high bleeding risk procedures 1

Special Considerations for Fracture Patients

Elderly patients with hip fractures present unique challenges:

• Often have unrecognized renal impairment requiring longer interruption 5
• May have taken dabigatran on day of injury, requiring 3-5 day wait 7
• Baseline anemia is common; DOAC patients arrive with lower hemoglobin 7
• Transfusion rates up to 40% reported in DOAC patients vs. 0% in controls 7

If surgery cannot be delayed (life-threatening fracture complications):

• Consider idarucizumab (specific dabigatran reversal agent) if available 4, 8
• Alternative: Prothrombin complex concentrates (PCC), though less effective 4, 6
• Hemodialysis can remove dabigatran effectively if time permits 6

The evidence from RE-LY trial (4,500 patients with dabigatran interruption) showed no increased perioperative bleeding compared to warfarin when following these protocols, with only 1% arterial thromboembolism rate 1.